Our findings further indicate that GA-MSC-mediated PD-L1 can be attenuated by Ad5-Ki67/IL-15 in treatment, thereby enhancing the effectiveness of immunotherapy in GBM. The gene discussed is MKI67; the disease is glioblastoma.